Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis

BACKGROUND: Canagliflozin, an oral agent that inhibits sodium glucose co-transporter 2, improves glycemic control, body weight, and blood pressure and is generally well tolerated in patients with type 2 diabetes mellitus (T2DM). This study extends the scope of previous analyses by evaluating outcome...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:BMC Endocr Disord
Prif Awduron: Buysman, Erin K., Chow, Wing, Henk, Henry J., Rupnow, Marcia F. T.
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2015
Pynciau:
Research Article
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4630836/
https://ncbi.nlm.nih.gov/pubmed/26527413
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12902-015-0064-8
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg